NCT03677973

A Study to Investigate the Safety of AB680 in Healthy Volunteers

A Double-Blind, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB680 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Arcus Biosciences, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a double-blind, randomized, placebo-controlled, single- and multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetic profile of AB680 in healthy volunteers.

Detailed description

AB680 will be administered as single and multiple intravenous doses to the healthy volunteers. In each group of 8 participants, 6 will receive AB680 and 2 will receive matching placebo. The participants will be closely observed to monitor the general tolerability of AB680.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	AB680	AB680 is a Cluster of Differentiation (CD)73 Inhibitor
OTHER	Placebo	Matching Placebo

Timeline

• Start date: 2018-10-16
• Primary completion: 2019-08-19
• Completion: 2019-08-19
• First posted: 2018-09-19
• Last updated: 2024-05-24

Locations

1 site across 1 country: Australia